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Abstract
Methotrexate has been a clinical agent used
in cancer, immunosuppression, rheumatoid
arthritis and other highly proliferative diseases
for many years, yet its underlying molecular
mechanism of action in these therapeutic areas
is still unclear. We present a chemical proteomics
approach that uses ultra-sensitive mass spec-
trometry coupled to an inverse protein-ligand
docking computational technique to unravel
the mechanism of action of this drug. Using
methotrexate tethered to a solid support we
were able to isolate a significant number of pro-
teins. We effectively captured a large portion of
the de novo purine metabolome and propose a
pathway architecture similar to that seen in sig-
naling pathways and consistent with substrate
channeling. More importantly, we were able to
capture protein targets that could potentially
provide new insights into the mechanism of
action of methotrexate in rheumatoid arthritis
and immunosuppression. The application of this
approach to other drugs and drug candidates
may facilitate the prediction of unknown and
secondary therapeutic target proteins and those
related to the side effects and toxicity. These
results demonstrate that this proteomics tech-
nology could play an important role in drug
discovery and development since it allows mon-
itoring of the interactions between a drug and
the protein content of a cell.
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Introduction
One of the most expensive, yet important
aspects of drug discovery and development is
the clinical evaluation of emerging therapeu-
tics. Yet, it is at this stage that most drug can-
didates fail to show efficacy or tolerable
toxicities and are withdrawn (1). Furthermore,
a large number of drugs already in clinical use
today have unknown or unclear molecular
mechanisms of action and toxicity. Precise
knowledge of the mechanism of action of
these drugs would facilitate critical decisions
to be made regarding label and patent expan-
sion, as well as the development of second-
generation therapeutics. A promising aspect of
the emerging field of proteomics is the devel-
opment of sensitive tools and methods for
facilitating an understanding of key interac-
tions between a drug and its targets at the
molecular level (2), thus allowing a better
decision-making process so that only com-
pounds with a high probability of showing the
required efficacy profile and low toxicity are
considered for the clinic.
Already, chemical proteomics, the capturing
of a select proteome with a chemical agent or
drug, has shown potential in accelerating drug
discovery and development (3,4). Recently, a
chemical proteomics approach was used to
identify the targets of the widely used quino-
lines and offered an insight into the mechanism
of action of these drugs (5). We are interested in
developing such methods and have access
to mass spectrometry instrumentation with
ultra-sensitivity (6). One of these methods is a
pharmaco-proteomics approach to understand-
ing the interaction between a drug and its tar-
gets. We have developed an affinity-based
chemical proteomics platform that uses small
molecules (e.g., a drugs or drug candidates)
attached to solid supports in such a way that
when exposed to a biological sample its inter-
acting protein partners can be captured and
identified. Captured proteins are isolated by
gel electrophoresis, readily analyzed by mass
spectroscopy and identified by searches against
sequence databases. With this technique, we
are able to identify proteins that are interacting
directly with the drug probe or interacting
indirectly via protein–protein engagement with
direct interactors. For the classification of direct
vs indirect interactions we have coupled our
experimental methods with a computational
technique termed inverse docking. This proce-
dure is used to dock a ligand against a library
of protein structures. Recently, this inverse
docking procedure was shown to be effective
in identifying potential new targets of 4H-
tamoxifen and vitamin E (7), respectively. This
tool has also been used to identify potential
toxicity and side effect-related protein targets
of a small molecule (8). With the advent of
structural genomics initiatives and given the
richness of protein structures already present
(9) in the protein database (http://www.rcsb.
org/pdb), we expect that the three dimensional
structures of many of the protein identified in
our experiments would be readily accessible or
predictable by homology modeling from
related protein structures. Proteins for which
inverse docking proposes binding modes rep-
resenting low energy complexes, as scored by a
consensus scoring technique (10) combining
five different score functions, are deemed hits
and worth considering as direct binders of the
ligand. 
To demonstrate the potential of combining
these two technologies, we selected the widely
used drug methotrexate (MTX). Methotrexate is
a folate antimetabolite that has been used exten-
sively for the treatment of highly proliferative
diseases such as rapidly growing tumors, acute
leukemia, rheumatoid arthritis, psoriasis, pneu-
mocystis carinii caused-pneumonia associated
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with AIDS, and other chronic inflammatory
disorders. Methotrexate has recognized effi-
cacy as an anti-inflammatory (11), immuno-
suppressive (12) and anticancer agent (13).
In inflammation and immunosuppression,
despite its wide use and several theories
behind its efficacy, the underlying molecular
mechanism of action of MTX remains unclear.
In cancer, the mechanism of action of MTX has
been understood as occurring because of cyto-
toxicity originating from the accumulation
of the corresponding polyglutamated MTX
metabolites in cells (14). Methotrexate is taken
into cells by reduced folate carrier (RFC)
protein, where it is polyglutamated by folyl-
polyglutamate synthetase (FPGS). Upon poly-
glutamation, MTX binds to dihydrofolate
reductase (DHFR) interrupting the conver-
sion of dihydrofolate to the activated N5,N10-
methylene-tetrahydrofolate. N5,N10-methylene-
tetrahydrofolate is the main methylene donor
in de novo purine biosynthesis, it provides
the methyl group in the conversion of
deoxyuridine-5’-monophosphate (dUMP) to
deoxythymidine-5′-monophosphate (dTMP)
for DNA synthesis and for many trans-
methylation processes. The polyglutamated
metabolite is subject to back glutamyl hydrol-
ysis by γ-GH and efflux from cells.
The three main targets of antifolate drugs
in the clinic are DHFR, thymidylate syn-
thase (TS), and glycinamide ribonucleotide
transformylase (GART) (15). Several newer
generation classical (polyglutamates) and
nonclassical (nonpolyglutamates) antifolate
drugs are now under clinical evaluation with
promising results (16). It is well known now
that MTX and other antifolates inhibit other
proteins besides DHFR, TS, and GART.
Amino-imidazolecarboxamide-ribonucleotide
transformylase (AICARFT) (17), serine hydroxy-
methyltransferase (SHMT) (18), FPGS (19),
γ-GH (20), and reduced folate carrier (RFC)
(21) are known to bind antifolates. 
The main problem with classical antifolates
is that accumulation of polyglutamated meta-
bolites causes drug resistance in cells. Several
mechanisms of resistance (22) defective trans-
port through cell membranes, amplification of
DHFR, reduced expression of FPGS and
upregulation of γ-GH have been identified as
the underlying basis for the development of
resistance to antifolates. Because of the increased
resistance with current antifolate drugs, there
is a need for new antifolate targets. The devel-
opment of clinical diagnostic markers for
antifolate drug resistant tumors would also be
beneficial in deciding which therapies to
choose for those tumors. Of equal importance
to clinical applications, is the understanding
of the molecular mechanism of action and
toxicity of existing and emerging antifolates
therapeutics.
In order to address some of these issues we
set out to investigate the underlying molecular
mechanism of action of MTX. Structurally, the
MTX-DHFR (23) (Fig. 1A) pair is one the best
understood ligand-protein systems and at the
time of writing a search of the protein data-
bank for the keyword MTX resulted in 66
entries. Most of these entries are of MTX or
derivatives in complexes with DHFR from dif-
ferent species and DHFR mutants, but struc-
tures for TS (1AXW)(24) also exist. The crystal
structure of GART in complex with a molecule
of glycinamideribonucleotide (GAR) and a
folate analog is also available (1CDE) (25). In
all these structures the aminopterin and the
α-carboxylate groups of the molecule are
buried inside the binding site and make key
hydrogen bond interactions with the protein,
while the γ-carboxylate group protrudes out of
the cavity (Fig. 2). For our studies, we used
the readily commercially available MTX
agarose reagent. This material is a mixture
resulting from linkages to the support through
the α- and γ-carboxylates of the molecule.
According to the structures of MTX com-
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plexes, we would expect that only the material
linked through the γ-carboxylate should be
productive in binding proteins from a cell
lysate, as the linkage through the α-carboxylate
would be stericly hindering if we assume a
similar binding conformation is required with
other proteins.
Methods
Preparation of Cell Lysates
HEK 293 cells (typically 107) were harvested,
washed with PBS, then lysed in a buffer con-
taining 20 mM Tris, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate supplemented with
protease inhibitors. After incubation for 30 min
at 4°C with shaking, the lysates were clarified
by centrifugation (27,000g). In some experi-
ments, cells were lysed using 20 strokes of a
Dounce homogenizer in the absence of deter-
gents, although since similar results were
obtained, detergent-based lysis was most-often
used. In most cases, proteins in the clarified
lysate were directly applied to MTX-affinity
columns (see section on Affinity Chromatogra-
phy). While optimizing the protocol, however,
several experimental variations were tested on
cell lysates including concentration by ammo-
nium sulfate precipitation, or removal of
nucleic acid with Streptomycin sulfate. In such
cases, the protein sample was desalted using a
PD 10 protein-desalting column (Pharmacia),
which had been pre-equilibrated in the same
buffer (10 mM potassium phosphate pH 7.5).
Affinity Chromatography
The desalted lysate was loaded onto a
column of pre-equilibrated MTX-agarose
(Sigma, 50 µL bed volume) or sepharose 4B
agarose as a negative control. The lysates was
allowed to slowly flow through the matrix
under gravity flow. The columns were then
washed with 4 × 0.6 mL of the same potassium
phosphate buffer with various concentrations
of NaCl (usually 0.4M but occasionally 1.0M),
followed by a quick rinse with 0.2 mL potas-
sium phosphate, 0.1M, pH 6.0; 100 mM NaCl
and eluted with 2 × 100 µL of 10 mM MTX
in potassium phosphate, 0.1M, pH 5.6; and
100 mM NaCl. Eluates containing the proteins
eluted by MTX were then concentrated by
spinning through microcon 3 (from Amicon).
Retentates from the microcons were then
loaded onto SDS-PAGE 4–15% gradient mini
gels (Bio-Rad). Gels were stained with Gel Code
Blue (Pierce), de-stained and imaged. Bands of
interest were excised, diced, trypsin digested
and sent for mass spectrometry analysis.
Protein Identification 
by Mass Spectrometry
Tryptic peptides recovered from individual
gel bands were separated by reverse phase
chromatography on C18 resin and directly
injected into a mass spectrometer with an
automated sample loading device from 96
well plates. Two types of mass spectrometry
platforms were used: (1) quadrupole ion traps
(LCQ Deca, Thermo Finnigan), and (2) cus-
tomized quadrupole time-of-flight hybrid
instruments (QSTAR Pulsar, MDS Sciex). Both
instrument types were operated in data-
dependent mode, which produces tandem MS
spectra of all peptide species present above a
programmed threshold. The spectra generated
were analyzed on a custom-built multi-node
server platform (RADARS, ProteoMetrics),
which uses two database searching programs,
Sonar (ProteoMetrics) and Mascot (Matrix Sci-
ences). The identities of the proteins were
obtained from database queries of the MS
derived data. The databases searched included
NCBI non-redundant protein, EMBL ensemble
predicted protein, NCBI human chromosomal,
and proprietary internal databases.
Docking Studies
Protein X-ray crystal structure coordinates
were downloaded from the protein data bank.
The corresponding pdb codes for the proteins
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Fig. 1. (A) Crystal structure of Methotrexate complexed within the active site of dihydrofolate reductase
showing the γ-carboxylate protruding out of the cavity. (B) Methotrexate molecule.
Fig. 2. Crystal structure of (A) MTX-DHFR (1RG7), (B) MTX-TS (1AXW), and (C) folate-GART (1 CDE),
respectively showing γ-carboxylate of methotrexate or folate derivative protruding out of the binding cavities
of all three enzymes.
Fig. 5. Overlap of docking poses (white) for methotrexate over the experimentally observed positions (gold)
for all proteins. RMS (Å) deviations were (A) 0.41 for mtx-DHFR (1RG7), (B.) 1.07 for mtx-TS-DUMP
(1AXW), and (C) 0.82 for folate-GART (1 CDE), respectively.
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used for the docking study are given in Table 1.
All waters of crystallization were removed
and all hydrogen atoms were added to the
proteins. Kollman-All charges were used for
all protein atoms using SYBYL (Tripos, St.
Louis, MO) and the protein file saved as a
Sybyl mol2 file. The initial conformation of the
MTX was extracted from the crystal structure
complex of dihydrofolate reductase and MTX
(1RG7). Coordinates for the molecule were
extracted, all atom types checked and corrected,
all hydrogens were added and Gasteiger-
Huckel charges were applied. For the inverse
docking procedure, the MTX molecule was
docked into the active sites of all proteins listed
in Table 1 using the standard default settings of
the program GOLD (CCDC, Cambridge, UK).
The resulting binding modes were visually
inspected for poses where the γ-carboxylate of
MTX protruded out of the binding site as
observed for DHFR and could be considered
compatible with binding. Scoring of the poses
was performed using the consensus-scoring
module CSCORE (Tripos, St. Louis, MO).
Results 
Conceptually, proteins may associate with
the immobilized ligand either through a direct
binding interaction or by an association with a
direct binding protein. The efficiency of the
interaction, as reflected in the amount of a pro-
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Table 1
Proteins Identified by Mass Spectrometrya
Known New proposed
folate targets of
Protein Identified targets methotrexate PDB codes
Dihydrofolate reductase (DHFR) √ 1RG7
Thymidylate Synthetase (TS) √ 1AXW
Glycinamideribonucleotide transformylase (GART) √ 1CDE
Aminoimidazole ribonucleotide synthetase (AIRS) 1CLI




Hypoxanthine phosphoribosyltransferase (HPRT) √ 1D6N
Deoxycytidine kinase √ 1P62
Deoxyguanosine kinase √ 1JAG
Pyridoxal kinase √ 1LHR
Glutamate-ammonia ligase (glutamine synthase) 1F52
Inosine monophosphate dehydrogenase (IMPDH) √ 1ME9
Pterin-4-α-carbinolamine dehydratase (PCD) √ 1DCP
Nudix 1 1G9Q
Nudix 5 √ 1KHZ
Divalent Cation tolerant protein CUTA 1P1L
Glutathione synthase 1GSA
Glycogen phosphorylase √ 1GGN
Propionyl CoA carboxylase Unknown
aCheck denotes new methotrexate targets.
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tein recovered, is a function of several param-
eters including both the abundance of the pro-
tein, its affinity for the MTX-loaded resin, and
the chromatographic and buffer conditions
employed. As expected, initial affinity-capture
experiments for MTX-interacting proteins
resulted in the isolation of a band on SDS-
PAGE that was identified by MS as DHFR.
DHFR was used as an internal control accord-
ing to which chromatographic conditions were
optimized for subsequent experiments. 
After optimal binding and elution con-
ditions were established, we were able to
reproducibly isolate a significant number of
proteins that associated with the immobilized
MTX probe, as indicated in the Coomassie-
stained gel in Fig. 3. The identity of the iso-
lated proteins was determined by MS analysis,
and the results are listed in Table 1 along with
the corresponding PDB code. 
In addition to DHFR, a second known MTX
target, GART, was identified. Many of the other
proteins identified, such as amidophosphoribo-
syltransferase, phosphoribosylaminoimidazole
(AIR) carboxylase, glycinamide ribonucleotide
synthase (GARS), aminoimidazole ribonu-
cleotide synthetase (AIRS), phosphoribosyl-
aminoimidazolesuccinocarboxamide (SAICAR)
synthase, hypoxanthine amidophosphoribosyl-
transferase (HGPRT) and inosine monophos-
phate dihydrolase (IMPDH) are enzymes
involved in either the de novo or salvage purine
synthesis pathways (Fig. 4). Interestingly, we
also identified glutamate ammonia ligase, an
enzyme involved in the production of glu-
tamine, a consumable used in nucleotide
Chemical Proteomics for Target Discovery _______________________________________________________ 51
Fig. 3. Protein signature or fingerprint of methotrexate probe. Lane A: molecular weight markers (kDa), lane B:
bands corresponding to proteins identified by mass spectrometry analysis.
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synthesis. Deoxycytidine kinase and deoxy-
guanosine kinase are also involved in DNA
synthesis. Other proteins also consistently
found were Pterin-4-α-carbinolamine dehy-
dratase (PCD), nudix 1, and nudix 5, CUTA,
pyridoxal kinase, glycogen phosphorylase and
glutathione synthase. Although not seen in ini-
tial experiments, we were able to identify TS
(a known MTX-interactor) after protocols were
adjusted to include 10 mM dUMP in the bind-
ing conditions. Finally, it should be noted that
several “background” proteins including het-
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Fig. 4. Diagram of purine and pyrimidine de novo and salvages pathways showing enzymes that have been iso-
lated by the methotrexate probe. Colored spheres represent different enzymes. Glutamine ammonia ligase
(grey),Amido phosphoribosyltransferase (lilac), GARS–AIRS–GART (cyan), DHFR (purple), SAICAR synthase-
AIR carboxylase (green), HPRT (red), and TS (orange). Empty circles represent enzymes in this pathway that
were not found, FGARAT, succino adenylo-succinate lyase, and AICART-IMP synthase.
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erogeneous nuclear ribonucleoproteins, actin,
tubulin, and heat shock proteins were also
identified in these experiments. These highly
abundant proteins are routinely identified by
our platform using agarose-based isolation
techniques and are not considered to be inter-
acting directly with the immobilized MTX.
Protein-MTX Docking
As expected, crystal structures for all but
one of the proteins captured in our experi-
ments were available from the protein data
bank. Similarly, all the crystal structures for the
proteins known to bind MTX that were not
identified in our experiments, except for RFC
protein, were available. As previously men-
tioned, the crystal structures of DHFR, TS,
and GART (Fig. 2) as complexes with MTX
or folates were available. Visual inspection of
these structures indicated that in all the struc-
tures the γ-carboxylate group protrudes out of
the active site cavity and is consistent with
affinity capture by our MTX probe. These
represented great tools for verifying the pre-
dictability of the docking exercise. If the dock-
ing exercise could reproduce the binding
modes experimentally observed in the X-ray
crystal structures of these three protein com-
plexes, then it is realistic to expect that docking
runs on other proteins would produce reason-
able solutions as well, and would predict direct
vs indirect binding. We performed inverse
docking of MTX or the folate molecule into the
binding site of the three proteins and investi-
gated the ten best docking poses for each. 
We found that in all three cases several
poses of the MTX or folate molecule approxi-
mated the experimentally observed positions
with a high degree of accuracy. The pose with
the greatest overlap over the experimentally
observed position was taken as correct and the
root mean square (RMS) deviation from the
experimentally observed positions measured.
RMS deviations (Å) were: 0.41 for MTX-DHFR
(1RG7), 1.07 for MTX-TS (1AXW), and 0.82 for
folate-GART (1CDE), respectively. Figure 5
shows the overlap between the acceptable
poses and the experimental positions for all
three proteins. This validation exercise indi-
cated that docking could indeed be a useful
tool in rationalizing the type of binding inter-
actions responsible for the recovery of the
MTX-associated proteins. In all cases in which
a crystal structure was available for the recov-
ered proteins, visual inspection of the struc-
ture followed by protein ligand docking was
performed. Proteins for which proposed bind-
ing modes represent low energy complexes,
compatible with the affinity ligand binding,
are deemed direct binders or targets of MTX.
Table 1 lists all the proteins for which docking
results predicted direct interactions and for
which evidence of MTX or folate binding was
present in the literature.
Discussion
Known Targets of MTX
Figure 4 shows a schematic representation
of the nucleotide de novo and salvage path-
ways highlighting the proteins (colored
spheres) that were identified in our experi-
ments. Remarkably, a great number of
enzymes involved in these pathways includ-
ing several enzymes that are not directly
dependent of folate cofactors were captured.
In essence this amounted to capturing a
metabolome. This suggests that this metabolic
pathway is effectively scaffolded together
through protein–protein interactions, possibly
as a means to facilitate forms of co-regulation
of the constituent enzymes and achieve a
more efficient anabolic process, as described
below (see section on Enzyme Channeling).
This is consistent with paradigms in both
signal transduction pathways, and pathways
for macromolecular biosynthesis, such as
DNA replication and transcription. 
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As expected, DHFR was identified as a
strongly staining band in the gel. The inter-
action between MTX and DHFR has been
measured at approx 10 nM (26). Addition of
10 mM dUMP to the medium facilitated the
recovery of another MTX target, TS. TS cataly-
ses the reductive methylation of dUMP to
dTMP, which is later phosphorylated to dTTP
for incorporation into DNA (27). This is a key
step in DNA synthesis and the only pathway
to dTMP. This protein is a major target of
several anticancer agents such as the widely
used dUMP derivative anticancer agent
5-flourouracil (FU). The rationale for dUMP
stimulating the association of TS with the
MTX matrix is that in the conversion of dUMP
to dTMP, in order for the methyl group trans-
fer to occur from an activated folate molecule
to dUMP, a complex needs to be formed in
which the molecular planes of folate and
dUMP are superposed via π–π stacking inter-
actions. Therefore the efficiency of MTX bind-
ing to TS is dependent on a π–π interactions
with dUMP. Consistent with this structural
observation and our results, the Kd for the
interaction of MTX with TS in the presence of
dUMP has been measured at 24.5 µM, but in
the absence of dUMP there is no detectable
interaction (28). 
The association of GART with the MTX
matrix was not surprising since it is one of
two folate dependent enzymes in the de novo
purine synthesis. This enzyme catalyses the
transfer of a formyl group from 10-formylte-
trahydrofolate to the amino group of glyci-
namide ribonucleotide (GAR). Hence, we
postulate this association is the consequence
of a direct interaction between GART and the
MTX ligand. Over the last decade or so, GART
has become and important target for anti-
cancer therapy.
New Proposed Targets of MTX
Besides DHFR, TS and GART, several new
proteins were identified that our inverse dock-
ing experiments suggest are new targets of
MTX. For most of these proteins, there is
also evidence in the literature for binding
by folates, MTX or MTX-derivatives, or by
chemotypes that can make similar hydrogen
bonding interactions as the pterin group of
MTX. The corresponding protein-MTX com-
plexes proposed by our inverse-docking pro-
cedure are presented in Figure 6. 
Amido Phosphoribosyltransferase
Amido phosphoribosyltransferase catalyses
the committed step in purine biosynthesis.
This enzyme catalyses the addition of an
amine group to phosphoribosylpyrohosphate
(PPRP). This transformation takes place as two
separate reactions at two distinct active sites
in this enzyme. The enzyme contains glutam-
inase activity in the N-terminal domain and
phosphoribosyl transferase in the C-terminal
domain. PPRP binds at the phosphoribosyl-
transferase site and causes a conformational
change in the enzyme allowing glutamine to
bind at the glutaminase site (29). The ammo-
nia generated at the glutaminase site is rapidly
channeled through the formation of a hydro-
phobic tunnel to the PPRP molecule posi-
tioned for nucleophilic attack by the incoming
NH3. The resulting phosphoribosylamine
(PRA) is a highly unstable intermediate under
physiological conditions and is rapidly trans-
ferred to the next enzyme in the pathway,
GARS, where it is converted to GAR. 
Amido phosphoribosyltransferase is subject
to feedback inhibition by end products of the
pathway AMP, GMP, and IMP through inter-
action at two allosteric binding sites with dif-
fering preference for AMP at one site and
GMP and IMP at the other. We performed
visual inspection followed by docking MTX at
both sites. Our docking experiments resulted
in several binding modes of MTX that are con-
sistent with binding at the GMP allosteric
binding site (1AO0) (30), but not at the AMP
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Fig. 6. Proposed binding modes for methotrexate complexes with proteins postulated to represent new tar-
gets of this drug (MTX is in orange and when applicable is superposed over the experimentally complexed
ligand from the X-ray structure. Only active site residues shown and some residues have been omitted for clar-
ity). (A) Amido phosphoribosyltransferase-ADP (lilac), GMP (light green); (B) IMPDH-IMP (lilac); (C) HGPRT-
GMP (lilac); (D) PCD-7,8-dihydrobiopterin (lilac); (E) glycogen phosphorylase-glucopyranose spirohydantoin
(light green), pyridoxal phosphate (lilac); (F) deoxyguanosine kinase-ATP (lilac); (G) deoxycytidine kinase-ADP
(lilac), prodrug AraC (light green); (H) pyridoxal kinase-ATP (lilac); and (J) Nudix 5.
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site. Our results are corroborated by evidence
in the literature that MTX inhibition of purine
de novo synthesis in leukemia cells occurs
before the folate dependent steps carried
out by GART and AICARFT. On treatment
with MTX the de novo pathway is completely
blocked, accumulation of GAR and AIRCAR
intermediates are minimal, whereas accumu-
lation of 5-phosphoribosyl-1-pyrophosphate is
three- to four-fold (31). This is consistent with
the interpretation that the enzyme being inhib-
ited by MTX is amido phosphoribosyltrans-
ferase. Further in vitro assays performed with
MTX-Glu5, the active metabolite of MTX in
cells also showed that amido phosphoribosyl-
transferase is inhibited (32).
A widely accepted mechanism of action for
low dose MTX in rheumatoid arthritis (RA) is
based on the theory that MTX mediates
adenosine release. This has been considered
secondary to the inhibition of AICARFT and
accumulation of AICAR. More recently it has
been shown that in addition to adenosine
release, MTX induces apoptosis of activated
T-cells in the S/G2 phase of the cell cycle (33).
A more recent study, in mitogen stimulated
T-lymphocytes, showed by radiolabeling stud-
ies of reaction intermediates that MTX blocks
the committed step in purine synthesis. The
authors postulate that direct inhibition of
amidophosphoribosyltransferase could be the
underlying mechanism for the efficacy of MTX
in RA (34). The fact that we consistently
isolated this enzyme under a variety of con-
ditions provides strong evidence of its
direct inhibition by MTX. This finding is of
paramount importance. If the inhibition of
amido phosphoribosyltransferase by MTX is
indeed responsible for the efficacy of this drug
in RA, this could present the pharmaceutical
industry with a new RA target and open wide
opportunities for the search of new drug
chemotypes that may be less prone to resis-
tance than MTX. Structure-based design
would be highly amenable because of the
knowledge of the three dimensional structure
of this enzyme. 
Inosine Monophosphate Dehydrogenase
(IMPDH) 
Our experiments identified both isoforms
IMPDH1 and IMPDH2. IMPDH catalyses the
nicotinamide adenosine dinucleotide depen-
dent conversion of inosine 5’-phosphate to
xanthosine 5’ phosphase, the first step in the
de novo synthesis of guanine nucleotides.
Rapid proliferating cells such as lymphocytes
depend on the availability of nucleotide pools.
It is known that the activity of IMPDH is
higher in rapid proliferating cells. Because of
these cell requirements, IMPDH has become
and important target for immunosuppressive,
anticancer and antiviral therapies. Several
IMPDH inhibitors are now being evaluated in
the clinic (35). Since this enzyme binds the
inosine moiety, and other enzymes that bind
IMP have been known to also bind folate
analogs, we postulate that MTX could bind
this enzyme directly. Docking MTX in the
recently solved crystal structure of the
IMPDH1 in complex with IMP (1ME9) (36)
generated several binding modes compatible
with direct binding to our affinity column. In
several poses the MTX molecule binds at the
IMP/XMP site of the protein with the pterin
group overlapping the position typically
occupied by the head group of the IMP/XMP
molecules and make similar hydrogen bond
interactions. The benzyl and glutamate groups
sit over the sugar and phosphate of IMP/XMP
and point towards the opening of the cavity.
The crystal structure of IMPDH with the
immunosuppressive inhibitor micophenolic
acid has revealed the mode of inhibition of
this agent. Micophenolic acid occupies the
NAD site of IMPDH and acts by blocking
the conversion of IMP to XMP (37). It is possi-
ble that MTX and micophenolic acid both
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derive their immunosuppressive activities by
inhibiting IMPDH but through slightly dif-
ferent molecular mechanisms. A provocative
possibility for the efficacy of MTX as an immu-
nosuppressive agent is that this effect may be
caused at least in part through direct inhibi-




ferase is the most important enzyme of
the salvage pathway. This enzyme catalyses
the salvage conversion of hypoxanthine and
guanine to IMP and GMP, respectively, by
facilitating the addition of the bases to the acti-
vated PPRP molecule (38). This enzyme, like
amidophosphoribosyltransferase, is involved
in amine addition to the PPRP. The activity
of salvage enzymes like HGPRT is higher
than the activity of enzymes involved in the
de novo pathways. It has been puzzling that
agents such as MTX, believe to act primar-
ily on de novo enzymes, are effective in spite
of the presence of highly active salvage
enzymes. This has recently been accounted
for, at least in part, by new observations show-
ing that MTX can reduce the activity of
HGPRT (39). Other observations suggest in
vivo inhibition of HPRT by MTX. For exam-
ple, deficiency in HGPRT is known to result
in higher levels of PRPP and an acceleration
of purine biosynthesis by the de novo pathway
(40). Treatment with MTX also produces an
increase on levels of PRPP (41) and this effect
is reversible upon treatment with hypoxan-
thine. Our docking experiments are also con-
sistent with direct binding as MTX can fit in
the binding pocket of HGPRT (1D6N) (42)
with good overlap over the positions occupied
by hypoxanthine monophosphate with the
glutamate group of MTX protruding out of the
cavity. The evidence in the literature and our
findings indicate direct inhibition of HGPRT
by MTX. This could contribute, at least in part,
to the efficacy of MTX as an anti-cancer agent.
Pterin-4-α-Carbinolamine 
Dehydratase (PCD)
PCD catalyses the dehydration of 4α-
hydrozytetrahydrobiopterins to the corre-
sponding dihydropterins. Dihydrobiopterin is
a substrate of pteridine reductase, an enzyme
known to bind MTX directly (43). Here we
speculate that because both enzymes bind
the same dihydrobiopterin, PCD is binding
directly to the MTX probe. Our docking exper-
iments on the structure of PCD from the crys-
tallographic complex with biopterin (1DCP)
(44) supports direct binding. In our docking
experiments, several docking poses were
found where the pterin moiety of MTX exactly
overlaps over the biopterin molecule in the
complex and the γ-carboxylate protrudes out
of the cavity. 
Glycogen Phosphorylase
Glycogen phosphorylase is involved in
glycogen metabolism that regulates blood glu-
cose levels and is an important therapeutic
target for diabetes. This enzyme catalyses the
phosphorylitic cleavage of glycogen to glyco-
gen phosphate. This enzymatic reaction uses
pyridoxal phosphate (PLP), a derivative of
vitamin 6. Methotrexate, 3′-chloro- and 3′,5′-
dichloromethotrexates and various folate
derivatives have been shown to be reversible
inhibitors of muscle glycogen phosphorylase b
(45). In this case, it is easy for us to argue that
glycogen phosphorylase is a direct binder of
the MTX probe. Our docking experiments on
the structure of glycogen phosphorylase
(1GGN) (46) also corroborates this hypothesis,
as MTX in several of the docking poses is
found with the γ-carboxylate protruding out
of the cavity. 
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Deoxyguanosine Kinase 
and Deoxycytidine Kinase
These enzymes are members of the deoxy-
ribonucleoside kinases that phosphorylate
deoxyribonucleosides, a crucial reaction in
biosynthesis of DNA precursors through the
salvage pathway. These kinases are of thera-
peutic interest as they are crucial in the acti-
vation of a number of anticancer and antiviral
pro-drugs such as 2-chloro-2′-deoxyadenosine,
azidothymidine and acyclovir (47). The crys-
tal structure of deoxycytidine kinase has been
recently solved (1P62) (48). Docking into the
substrate binding site of deoxycytidine kinase
produced binding modes where the complete
MTX molecule bound as a bisubstrate, by
blocking both substrate and ATP binding site.
In all cases the γ-carboxylate points towards
the entrance to the ATP binding site overlap-
ping with the adenine ring. These binding
modes are consistent with direct binding. This
is consistent with observations that treatment
with MTX increases the concentration of
deoxycytidine triphosphate pools in L1210
ascites cells (49). It has already been suggested
that MTX could be potentiating this effect by
allosteric regulation of deoxycytidine kinase.
Our results indicate that direct inhibition of
deoxycytidine kinase is the most likely cause
of the increased deoxycytidine triphosphate
pools. 
Likewise the structure of deoxyguanosine
kinase (1JAG) (50,51) is available. Interestingly,
the crystal structure of deoxyguanosine kinase
in complex with ATP showed the ATP mole-
cule sitting in the substrate binding site rather
than in the expected ATP binding site. This
indicates that this subsite is quite flexible in
accommodating molecules with differing
chemotypes. Docking MTX in the site resulted
in structures quite similar to those observed
in the structurally conserved deoxycytidine
kinase. This further corroborates that these
two kinases are likely being isolated in our
experiments through direct interactions with
our MTX affinity probe. 
Pyridoxal Kinase
We identified another PLP requiring
enzyme, pyridoxal kinase. This enzyme cat-
alyzes the conversion of pyridoxal to pyri-
doxal-5’-phosphate (PLP). PLP is an important
cofactor in a variety of reactions such as
decarboxylations, deaminations, transamina-
tions, racemizations and aldol cleavages.
Pyridoxal kinase shows up consistently as an
intense band on our gels. The crystal structure
of pyridoxal kinase was recently solved
(1LHR) (52) in complex with the ATP analog
AMP-PNP. Docking in the ATP binding site of
pyridoxal kinase generated several binding
poses suggestive of direct binding. In these
poses the MTX overlaps well over the position
of AMP-PNP and the pterin group makes sim-
ilar hydrogen bonding contacts to the backbone
atoms in the hinge region. The γ-carboxylate
points towards the solvent exposed region on
the kinase active site or cleft. It is our view
that pyridoxal kinase is another direct binder
of MTX. This is consistent with observations
that alkylxanthines are ATP competitive inhi-
bitors of pyridoxal kinase (53). As already
argued earlier for HGPRT, the pterin group
of MTX can act as a substitute of the xan-
thine moiety. Furthermore, extensive medici-
nal chemistry work done on antimetabolite
research has elucidated that the pterin ring
can be replaced with xanthine and xanthine-
like moieties. Examples of this are Peme-
trexed, (ALIMTA, LY-231514) the classical
antimetabolite TS inhibitor drug from Lilly
(54) and Tomudex (ZD9331) the nonclassical
TS inhibitor from AstraZeneca (55). Further-
more, the fact that another PLP dependent
enzyme, glycogen phosphorylase, binds MTX
further corroborates that pyridoxal kinase is
most likely binding through a direct interac-
tion with the tethered MTX molecule.
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Nudix 1 and 5
Nudix hydrolases are housekeeping pro-
teins involved in the hydrolysis of nucleoside
phosphates. Nudix-1 (MTH1) for example,
hydrolyses 8-oxo-dGTP and thus avoids errors
caused by their misincorporation during DNA
replication or transcription, which may result
in carcinogenesis or neurodegeneration (56).
Nudix 5 hydrolyses ADP sugars to AMP and
sugar-5-phosphates. Nudix hydrolases that
degrade dinucleosides and diphosphoinositol
polyphosphates also have 5-phosphoribosyl
1-pyrophosphate (PRPP) pyrophosphatase
activity that generates the glycolytic activator
ribose 1,5-bisphosphate (57). The fact that
these enzymes bind nucleotides and PRPP,
two substrates already encountered in several
other of the targets believed to be direct inter-
actors of MTX, and their role in purine and
pyrimidine synthesis is significant. Several
crystal structures examples for ADP nudix
hydrolases are available in the protein data-
bank, but none that represent 8-oxo-dGTP
hydrolase (58). We obtained the crystal struc-
ture of an ADP nudix hydrolases (nudix 5,
1KHZ) (59) and docked MTX into the nucle-
otide binding site. Interestingly, poses of
MTX were found that are consistent with a
direct interaction. The glutamate group can
protrude out of the cavity, while the amino-
pterin group is buried well within the binding
site making strong hydrogen bonding interac-
tions. Although there is no evidence in the lit-
erature that nudix hydrolases bind folates or
MTX, we believe that the presence of these
proteins (at least nudix 5) in our gels is result-
ing from direct interactions with the MTX
probe. 
Proteins Not Directly Associated
With MTX
The following proteins were captured in our
experiments, but visual inspection of their
crystal structure, inverse-docking and litera-
ture searches all indicate that their presence in
our gels were likely a consequence of indirect
binding with a direct MTX interactor. In par-
ticular, several of these were part of multifunc-
tional proteins of the de novo purine synthetic
pathway that are likely identified due to indi-
rect interactions with other MTX binding pro-
teins. For example AIRS and GARS are part of
a trifunctional enzyme, which contains the
direct interactor GART domain.
Aminoimidazoleribonucleotide (AIR) 
Carboxylase
AIR carboxylase catalyses the carboxylation
of aminoimidazoleribonucleotide (60). The
domain associated with this enzymatic activity
in animals is part of a bifunctional polypep-
tide containing SAICAR synthase and AIR
carboxylase. In our experiments a single band
contained peptides from both domains of the
bifunctional enzyme. The crystal structure of
Air carboxylase (1D7A) (61) is available from
the protein databank in complex with AIR.
Docking runs of MTX in the air binding-site
resulted in several poses that could also be
compatible with binding. In these poses the
pterin moiety of MTX is perpendicular to
the imidazole ring of Air, but the γ-carboxylate
does protrude out of the cavity. Because of this
perpendicular binding, it is hard to postulate
that this is a direct binder. We believe, how-
ever, that AIR carboxylase was captured due
to protein–protein association with GARS–
AIRS–GART through the GART domain. 
Phosphoribosylaminoimidazolesuccino-
carboxamide (SAICAR) Synthase
This enzyme catalyses the seventh step in
the de novo biosynthesis of purine nucleotides.
The crystal structure of SAICAR synthase
(1A48) (62) reveals that its active site is a very
open cleft. There is no precedence in the liter-
ature for direct binding of SAICAR to folates
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or MTX. Docking experiments resulted only in
poses in which the complete MTX molecule is
buried deep into the cleft. In all poses both
carboxylate groups are involved in hydrogen
bonding interactions and fully buried inside
the protein and would therefore interfere with
binding to the attached MTX. 
Glycinamideribonucleotide Synthase
(GARS)
As mentioned earlier, the second, third, and
fifth steps of de novo purine biosynthesis are
catalyzed by a trifunctional protein GARS–
AIRS–GART (63). GARS catalyses the second
step of the de novo purine biosynthetic path-
way, the conversion of phosphoribosylamine,
glycine, and ATP to glycinamide ribonu-
cleotide (GAR), ADP, and Pi. We isolated pep-
tides for GARS as part of the trifunctional
protein GARS–AIRS–GART, but also as a sep-
arate band of 50 kDa in the gel. Transfection
of chinese hamster ovaries (CHO) cell with the
human GARS–AIRS–GART gene, has shown
that this gene encodes not only the trifunc-
tional protein of 110 kDa, but also a mono-
functional GARS protein of 50 kDa produced
by alternative splicing resulting in the use of a
polyadenylation site in the intron between the
terminal GARS and the first AIRS exons (64).
The mechanism of MTX binding was also
investigated by docking experiments on the
crystal structure of GARS (1GSO) (65). This
protein, like SAICAR synthase has a very
large open binding site, and no docking con-
formations were found where MTX could
form productive stable complex with GARS.
Since we found GARS as a separate band and
docking experiments were inconclusive, it is
difficult to postulate a direct binding mecha-
nism. Eben though GART and GARS are part
of the same trifunctional protein, there may be
a protein–protein docking interaction between
the domains. Protein–protein interactions
between the first and second enzymes in
purine biosynthesis, amido phosphoribosyl-
transferase, and GARS, have also been postu-
lated. Phosphoribosylamine is the product of
the first enzyme and the substrate for the next
reaction in the purine biosynthesis chain of
events. There is evidence that this phosphori-
bosylamine reagent transfer occurs from one
enzyme to the next via a coupling between
Amidophosphoribosyltransferase and GARS,
rather than through free diffusion (66). This
presents a second possible mechanism for the
association of GARS with MTX, and it is




This enzyme is also part of the trifunctional,
GARS–AIRS–GART protein. Docking runs on
the crystal structure of AIRS (1CLI) (67) does
not indicate direct binding with the MTX
probe. We postulate that the presence of this
enzyme is simply due to the fact that it is part
of the trifunctional protein GARS–AIRS–
GART.
Gluthathione Synthase
Interestingly glutathione synthase is struc-
tural related to SAICAR synthase (68). Struc-
tural comparisons of these two proteins reveal
a common fold. This fold is also shared with
heat shock protein HSP70. HSP70 and HSP60
were also identified in these experiments, but
since these proteins are commonly found in
other experiments unrelated to the MTX
probe, we excluded them from our discussion.
However, because of the structural similarity
with SAICAR synthase and Gluthathione syn-
thase, it may be that these proteins are being
pulled down by the same mechanism. The
crystal structure of glutathione synthase is
available (1GSA) (69) and was used in dock-
ing exercises that were also inconclusive. In all
docking modes the complete MTX molecule is
completely buried deep within a very closed
active site pocket. 
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Propionyl CoA Carboxylase and Divalent
Cation Tolerant Protein (CUTA)
These proteins are pulled down consistently
in our experiments. The crystal structure of
proprionyl CoA carboxylase is not known
and a literature search does not show previ-
ous evidence of any interaction between MTX
and this enzyme. The crystal structure of
CUTA was recently solved and is available
(1P1L) (70) as part of a structural genomics
initiative, however the function of this enzyme
is yet not understood. Docking of MTX in this
crystal structure was inconclusive.
Known Folate Binders Not Identified 
As discussed earlier, folates and antifolates,
such as MTX are known to bind or be pro-
cessed by several folate-binding proteins not
captured in our experiments. To our surprise,
our experiments failed to isolate AICARFT,
SHMT, FPGS, γ-GH, and RFC. Inspection of
their corresponding crystal structures and
knowledge of the mechanism of catalysis of
these enzymes allowed us to rationalize the
reason for their absence. Inspection of the
recently solved crystal structure of AICARFT
with a multisubstrate folate inhibitor (1OZ0)
(71) indicates that while the γ-carboxylate of
the molecule points out of the cavity, it does
not protrude far enough to preclude possible
steric interaction of surrounding protein
sidechains with the MTX matrix. Furthermore,
it is known that MTX is only a weak inhibitor
of AICARFT as compared to other targets. The
case for FPGS (1JBW) (72) and γ-GH (1L9X)
(73) is easier to make as the crystal structures
of these two proteins have been solved and
their mechanism of catalysis are now well
understood. The glutamate sidechain of MTX
and folates needs to point into the cavity in
order for polymerization or hydrolysis to
occur, a condition incompatible with binding
our MTX affinity probe. The crystal structure
of Serine Hydroxymethyltransferase in com-
plex with glycine and 5-formyl tetrahydro-
folate is also available (1DFO) (74). In this
structure the pteridine ring is buried in the
active site, but the γ-carboxylate protrudes
well out of the cavity in a way that would be
expected to bind the MTX probe. However, it
is well known that the folate-independent
cleavage of L-serine substrates is competitively
inhibited by 5-formyl-H4PteGlu(n), but with
dependence on the length (n) of the polyglu-
tamate chain. For monoglutamates inhibition
is immediate, but for n = 3 inhibition is very
slow (75). We believe that the matrix in our
MTX probe may be mimicking a long poly-
glutamate chain and that the time scale of
our experiments is not long enough to
observe binding. In the case of the membrane-
imbedded reduced folate carrier there is no
crystal structure available and the mechanism
of folate transport is not completely clear (76).
We adopted protocols (not shown) specifically
for isolating proteins from membrane fractions
but persistently failed to isolate this protein.
The Purine Metabolone: Proposal 
of Enzyme Complexes for Substrate
Channeling
The concept of substrate channeling (77), or
rather the transfer of metabolites between con-
secutive enzymes in a reaction pathway is a
topic of much controversy. While inter-domain
channeling within a single enzyme, as seen in
the ammonia transfer between the glutaminase
and the phosphoribosyltransferase active sites
in amido phosphoribosyltransferase, is well
established as a result of recent crystallographic
evidence for the formation of a hydrophobic
channel connecting the two active sites (78),
channeling between two consecutive enzymes
in a reaction pathway is less understood. Part
of the controversy of inter-enzyme channeling
arises from the fact that within systems
reported to be involved in channeling, interact-
ing enzymes do not form stable complexes. It
has been proposed that in these systems the
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channeling is a dynamic process involving an
encounter between the enzyme–substrate com-
plex and the next enzyme occurring at a faster
rate than the process of free diffusion of sub-
strate from the first enzyme into the medium
followed by complex formation with the
second enzyme (79). Although there has been
no direct evidence for formation of a complex
between amido phosphoribosyltransferase and
GARS under reaction conditions, a channeling
mechanism has been proposed for the transfer
of phosphoribosylamine (PRA) from amido
phosphoribosyltransferase to GARS (80). PRA
is highly unstable under physiological condi-
tions and therefore needs to be protected from
the medium via the formation of a transient
channel between these two enzymes so that it
can be quickly transformed into the stable
intermediate GAR by GARS. We propose that
the identification of a least three proteins con-
taining enzymatic activity for six steps in the
de novo purine synthesis pathway may repre-
sent evidence for a pathway architecture that
is consistent with substrate channeling (77,81),
given that only one is known to be inhibited
by antifolate metabolites such as MTX. Already
substrate channeling has been proposed for
GARS and amido phosphoribosyltransferase.
GARS is part of a trifunctional protein also
containing activities for AIRS and GART
respectively. This trifunctional protein catalyzes
the second, third, and fifth step in de novo syn-
thesis. There is evidence for GART interaction
with MTX, but not for GARS and AIRS. We did
not find evidence in our experiments for the
presence of the fourth enzyme in the pathway,
FGARAT, but we did find the bifunctional pro-
tein containing activities for AIR carboxylase
and SAICAR synthase, that catalyze the sixth
and seventh steps in the pathway. We could
not find evidence in the literature for direct
inhibition of either AIR carboxylase or SAICAR
synthase by MTX or folate analogs. Further-
more, our docking experiments suggest that
this protein was isolated because of secondary
interactions with a MTX binding protein as a
binding mode indicating direct binding was
not found. We believe that this protein is
specifically interacting with GARS–GART–
AIRS, likely via interactions through the AIRS
domain, which comes a step before AIR car-
boxylase in the sequence. We propose that
enzymes bound to MTX directly are likely to
represent inhibited states whose structures may
be are more compatible with engaging other
enzymes in the pathway via stable protein–
protein interactions. 
We did not identify succino adenyl synthase,
the eighth enzyme in the pathway or the
bifunctional protein containing activities for
the folate-dependent enzyme AICARFT and
IMP cyclohydrolase, that catalyze the ninth
step and the tenth step in de novo purine syn-
thesis, respectively. It is known, however, that
MTX is a weaker inhibitor of AICARFT than
other folate dependent enzymes in the path-
way. Examination of the crystal structure of
AICARFT with a folate analog suggest that
the position of the γ-carboxylate may be too
buried in the enzyme to preclude MTX bind-
ing because of possible steric interactions with
the matrix. 
The functions of the enzymes of de novo
purine synthesis pathway have been well
studied, however, the underlying structural
organization of these enzymes is less well
understood. It is reasonable to expect that a
high degree of scaffolding is engineered into
these structures that is consistent with sub-
strate channeling from one enzyme to another
in order to protect unstable reactive interme-
diates from solvent and for reaction efficiency.
It has also been proposed that substrate chan-
neling helps direct the flux of a pathway
by eliminating the competition from other
enzymes for common metabolic intermediates.
It is conceivable that MTX as an inhibitor
may stabilize the structure of those enzymes it
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binds resulting in conformations more con-
ducive to stable complex formation with other
enzymes in the pathway. By identifying such
a large portion of this pathway we present
evidence that the enzymes of the purine
biosynthesis pathway are scaffolded together in
a manner consistent with substrate channeling.
Conclusions
Methotrexate is an important drug with
applications in several therapeutic areas with
unmet medical needs. The efficacy of this drug
in many cases has been arrived at serendipi-
tously. Although it has been widely used
in rheumatoid arthritis and immunosuppres-
sion a clear mechanism of action is not yet
available. We were able to identify the three
main therapeutic targets of antifolate therapies
in the clinic in a single experiment. It has been
postulated that MTX is able to interact with at
least eight other proteins not widely regarded
as targets of this drug but with crucial roles in
medicine and drug discovery. Inhibition of
IMPDH by MTX, for example, may be the
underlying reason behind its efficacy as an
immunosuppressive agent, and inhibition of
the first enzyme in the de novo synthesis of
nucleotides, amidophosphoribosyltransferase
may be responsible at least in part for its effi-
cacy in Rheumatoid arthritis. 
Another aspect we believe has paramount
importance is the capture in a single experi-
ment of such a large portion of the de novo and
salvage nucleotide synthesis pathways. Six of
the ten steps in purine synthesis are carried out
by enzymes identified with our drug probe.
This remarkable finding indicates that these
proteins, like signal transduction proteins, are
structurally engineered in such a way as to
facilitate the transfer of the evolving reagent
(purine) from one enzyme to the next via
tandem protein–protein recognition events.
Furthermore, the fact that so many of the pro-
teins identified in these experiment represent
viable drug discovery targets in the pharma-
ceutical industry underlines the effectiveness of
this technique in target discovery. The applica-
tion of this approach to other drugs and drug
candidates may facilitate the prediction of
unknown and secondary therapeutic target
proteins and those related to the side effects
and toxicity. These results demonstrate that our
proteomics technology could play an important
role in drug discovery since it allows monitor-
ing of the interactions between a drug and the
protein content of a cell with affinities over a
very large dynamic range as indicated by iden-
tifying DHFR (Kd approx 10 nM) and TS (Kd
approx 25 µM). This technology has particular
promise as a tool to stratify patient populations
for clinical studies by developing drug protein
fingerprints that can be correlated with patient
compliance. Drug response is a very complex
event. A drug’s proteomics fingerprint repre-
sents a Pharmaco-dynamic/Pharmaco-kinetic
filter that allows only relevant proteins to be
monitored. By monitoring a full compliment of
proteins that interact with a drug the underly-
ing reason for response may be revealed.
We would like to acknowledge Robert Rot-
tapel, Daniel Figeys, David Stover, Henry
Duewel, Olga Ornatsky, and Irving Sucholeiki
for helpful discussions during this work.
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